In addition, PUFAs through modulating endothelium-relaxing, stimulating the production of gasotransmitters leading to vasorelaxation such as nitric oxide (NO) and hydrogen sulphide, and decreasing the production of endothelin 1 and angiotensin II as vasoconstricting factors can improve endothelial dysfunction and atherosclerosis [16, 21]. The gene discussed is AGT; the disease is endothelial dysfunction.